Number of the records: 1
Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma.
- 1.
SYSNO ASEP 0091826 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Ostatní články Title Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma. Title Hodnocení FavId, individuálně specifické vakcíny pro léčení lidských nehodgkinských lymfomů Author(s) Reiniš, Milan (UMG-J) RID Source Title Current Opinion in Molecular Therapeutics - ISSN 1464-8431
Roč. 9, č. 3 (2007), s. 291-298Number of pages 8 s. Language eng - English Country GB - United Kingdom Keywords non-Hodgkin's lymphoma ; lymphoma vaccine FavId Subject RIV EB - Genetics ; Molecular Biology CEZ AV0Z50520514 - UMG-J (2005-2011) Annotation Favrille Inc is developing FavId, a patient-specific immunotherapy combining tumour-specific idiotype protein and keyhole limpet hemocyanin, for the potential treatment of lymphoma. Evaluation of this FavId drug has shown that a patient-specific idiotypic vaccine represents a therapeutic agent with clinical potential not only against non-Hodgkin's lymphoma but against other forms of B-cell malignancies, for example, chronic lymphocytic leukemia, mantle cell lymphoma or diffuse large-cell lymphoma. Workplace Institute of Molecular Genetics Contact Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Year of Publishing 2008
Number of the records: 1